{"product_id":"002422sz-business-model-canvas","title":"Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ): Canvas Business Model","description":"\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. stands as a formidable player in the pharmaceutical landscape, leveraging its robust business model to drive innovation and growth. With a keen focus on cutting-edge research, strategic partnerships, and a diverse customer base, Kelun is reshaping the healthcare narrative. Explore how each component of their Business Model Canvas intricately weaves together to create value in a competitive market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. actively collaborates with various external entities to further its business objectives and enhance its market position. Key partnerships play an essential role in driving innovation, ensuring quality, and navigating the complex pharmaceutical landscape.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions Collaboration\u003c\/h3\u003e\n\n\u003cp\u003eKelun has established strategic collaborations with numerous research institutions to bolster its R\u0026amp;D capabilities. This approach allows the company to innovate new drugs and improve existing formulations. Notably, in 2022, Kelun partnered with \u003cstrong\u003e8 research institutions\u003c\/strong\u003e, focusing on oncology and cardiovascular diseases. These collaborations have contributed to an increase in the company’s R\u0026amp;D expenditure, which reached approximately \u003cstrong\u003e¥2.5 billion\u003c\/strong\u003e (around \u003cstrong\u003e$368 million\u003c\/strong\u003e) in 2022.\u003c\/p\u003e\n\n\u003ch3\u003eStrategic Alliances with Healthcare Providers\u003c\/h3\u003e\n\n\u003cp\u003eKelun has formed strategic alliances with a variety of healthcare providers, including hospitals and clinics. These partnerships facilitate the distribution of Kelun's products and enhance patient access to innovative therapies. In 2021, Kelun reported a significant partnership with a leading healthcare provider network that encompasses over \u003cstrong\u003e300 hospitals\u003c\/strong\u003e across China. This alliance has led to an increase in sales volume, contributing to a revenue growth of \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year in the company’s hospital sales segment.\u003c\/p\u003e\n\n\u003ch3\u003eSuppliers of Raw Materials\u003c\/h3\u003e\n\n\u003cp\u003eFor pharmaceutical production, reliable suppliers of raw materials are critical. Kelun collaborates with several key suppliers to ensure the quality and consistency of its raw materials. In 2023, the company signed long-term supply agreements with \u003cstrong\u003e5 major suppliers\u003c\/strong\u003e, which account for over \u003cstrong\u003e60%\u003c\/strong\u003e of its raw material needs. This strategic move has enabled Kelun to stabilize its production costs amidst fluctuating market prices, ensuring a consistent supply chain. The average raw material cost for Kelun was approximately \u003cstrong\u003e¥1.8 billion\u003c\/strong\u003e (around \u003cstrong\u003e$264 million\u003c\/strong\u003e) in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eNumber of Partners\u003c\/th\u003e\n        \u003cth\u003eExpenditure\/Revenue Impact\u003c\/th\u003e\n        \u003cth\u003eKey Focus Areas\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003e8\u003c\/td\u003e\n        \u003ctd\u003e¥2.5 billion\u003c\/td\u003e\n        \u003ctd\u003eOncology, Cardiovascular\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e300+ hospitals\u003c\/td\u003e\n        \u003ctd\u003e12% growth\u003c\/td\u003e\n        \u003ctd\u003eInnovative Therapies\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSuppliers of Raw Materials\u003c\/td\u003e\n        \u003ctd\u003e5\u003c\/td\u003e\n        \u003ctd\u003e¥1.8 billion\u003c\/td\u003e\n        \u003ctd\u003ePharmaceutical Production\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. operates in the pharmaceutical sector, focusing on various key activities essential for delivering value to its customers. The company's activities can be categorized into three main areas: pharmaceutical research and development, manufacturing and production, and marketing and distribution.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\n\u003cp\u003eResearch and development are critical for Kelun, as they strive to develop innovative drug solutions. In 2022, the company's R\u0026amp;D expenditure was approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, reflecting a commitment of about \u003cstrong\u003e10%\u003c\/strong\u003e of their total revenue. This investment has resulted in the launch of several new drugs, contributing to a portfolio of over \u003cstrong\u003e200\u003c\/strong\u003e products.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing and Production\u003c\/h3\u003e\n\n\u003cp\u003eKelun boasts advanced manufacturing capabilities with over \u003cstrong\u003eEight\u003c\/strong\u003e production bases strategically located across China. The company’s total production capacity exceeds \u003cstrong\u003e10 million\u003c\/strong\u003e units annually. In 2022, the manufacturing revenue reached approximately \u003cstrong\u003eRMB 9.3 billion\u003c\/strong\u003e, highlighting effective scaling of operations.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Manufacturing Metrics\u003c\/th\u003e\n        \u003cth\u003e2021\u003c\/th\u003e\n        \u003cth\u003e2022\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Production Capacity (units)\u003c\/td\u003e\n        \u003ctd\u003e8 million\u003c\/td\u003e\n        \u003ctd\u003e10 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Revenue (RMB)\u003c\/td\u003e\n        \u003ctd\u003eRMB 8.7 billion\u003c\/td\u003e\n        \u003ctd\u003eRMB 9.3 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNumber of Production Bases\u003c\/td\u003e\n        \u003ctd\u003e6\u003c\/td\u003e\n        \u003ctd\u003e8\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\n\u003cp\u003eKelun employs a comprehensive marketing strategy that includes both online and offline channels. In 2022, the marketing budget was recorded at around \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e. The company has established partnerships with over \u003cstrong\u003e200\u003c\/strong\u003e distributors nationwide, enabling them to reach over \u003cstrong\u003e30,000\u003c\/strong\u003e pharmacies and healthcare institutions in China.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, Kelun’s market share in the Chinese pharmaceutical market has grown by \u003cstrong\u003e15%\u003c\/strong\u003e from 2021 to 2022, positioning them as one of the top pharmaceutical companies in the region.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eMarketing and Distribution Metrics\u003c\/th\u003e\n        \u003cth\u003e2021\u003c\/th\u003e\n        \u003cth\u003e2022\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing Budget (RMB)\u003c\/td\u003e\n        \u003ctd\u003eRMB 450 million\u003c\/td\u003e\n        \u003ctd\u003eRMB 500 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNumber of Distributors\u003c\/td\u003e\n        \u003ctd\u003e180\u003c\/td\u003e\n        \u003ctd\u003e200\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies and Institutions Reached\u003c\/td\u003e\n        \u003ctd\u003e25,000\u003c\/td\u003e\n        \u003ctd\u003e30,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarket Share Growth (%)\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eSichuan Kelun Pharmaceutical Co., Ltd.\u003c\/strong\u003e is a prominent player in the pharmaceutical industry, particularly known for its focus on innovative drug development and manufacturing. The company's key resources are fundamental to its operation and success.\u003c\/p\u003e\n\n\u003ch3\u003eCutting-edge Research Facilities\u003c\/h3\u003e\n\n\u003cp\u003eSichuan Kelun has invested significantly in its research and development (R\u0026amp;D) infrastructure. As of 2022, the company reported a total expenditure of approximately \u003cstrong\u003eRMB 1.1 billion\u003c\/strong\u003e (around USD \u003cstrong\u003e170 million\u003c\/strong\u003e) on R\u0026amp;D. The company operates multiple state-of-the-art research facilities that are equipped with advanced technology for drug discovery and formulation.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce and R\u0026amp;D Teams\u003c\/h3\u003e\n\n\u003cp\u003eThe workforce at Sichuan Kelun is a vital asset. The company employs over \u003cstrong\u003e9,000\u003c\/strong\u003e skilled professionals, including scientists, researchers, and engineers, dedicated to R\u0026amp;D efforts. Approximately \u003cstrong\u003e1,200\u003c\/strong\u003e of these employees are directly involved in R\u0026amp;D teams, contributing to the innovation pipeline and enhancing the company’s competitive edge in the market.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\n\u003cp\u003eIntellectual property is another cornerstone of Sichuan Kelun's business model. The company holds more than \u003cstrong\u003e300 patents\u003c\/strong\u003e in various therapeutic areas, including oncology and cardiovascular diseases. In 2022, the company reported an increase in patent filings by \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year, highlighting its commitment to protecting its innovations. The patent portfolio not only secures revenue streams through potential licensing agreements but also fortifies the company’s market position.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eValue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Facilities\u003c\/td\u003e\n        \u003ctd\u003eState-of-the-art equipment and technology for drug development\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.1 billion (USD 170 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n        \u003ctd\u003eOver 9,000 employees with 1,200 in R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eLabor cost estimated at RMB 800 million (USD 120 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatents\u003c\/td\u003e\n        \u003ctd\u003eMore than 300 patents in key therapeutic areas\u003c\/td\u003e\n        \u003ctd\u003ePotential licensing revenue of RMB 200 million (USD 30 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, renowned for its focus on delivering high-quality pharmaceutical products. The company's offerings are designed to meet the diverse needs of healthcare providers and patients.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality pharmaceutical products\u003c\/h3\u003e\n\u003cp\u003eSichuan Kelun Pharmaceutical has demonstrated a commitment to quality through its adherence to stringent regulatory standards. In 2022, the company reported a manufacturing capacity of over \u003cstrong\u003e10 billion tablets\u003c\/strong\u003e and \u003cstrong\u003e5 billion capsules\u003c\/strong\u003e annually. The company's product line includes essential medicines that encompass over \u003cstrong\u003e200 registered products\u003c\/strong\u003e, catering to various therapeutic areas, including oncology, cardiology, and infectious diseases.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative drug formulations\u003c\/h3\u003e\n\u003cp\u003eInnovation is central to Sichuan Kelun's value proposition. In 2023, the company invested over \u003cstrong\u003eCNY 1 billion\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 150 million\u003c\/strong\u003e) in research and development, focusing on novel drug formulations and delivery systems. This investment has led to the introduction of several new products, including a groundbreaking \u003cstrong\u003elong-acting injectable formulation\u003c\/strong\u003e for the treatment of chronic illnesses, which has garnered significant attention from healthcare professionals. The company holds over \u003cstrong\u003e100 patents\u003c\/strong\u003e related to drug formulations and therapies.\u003c\/p\u003e\n\n\u003ch3\u003eCost-effective healthcare solutions\u003c\/h3\u003e\n\u003cp\u003eSichuan Kelun Pharmaceutical positions itself as a provider of cost-effective healthcare solutions. In 2022, the company's average selling price for generic drugs was approximately \u003cstrong\u003eCNY 3.5\u003c\/strong\u003e (around \u003cstrong\u003eUSD 0.50\u003c\/strong\u003e) per unit, making it competitive in the market. The gross profit margin for its generic pharmaceutical segment stood at \u003cstrong\u003e60%\u003c\/strong\u003e, reflecting the company's operational efficiency. As part of its cost-saving initiatives, the company has implemented lean manufacturing processes, which have reduced production costs by approximately \u003cstrong\u003e15%\u003c\/strong\u003e over the past three years.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eR\u0026amp;D Investment (CNY)\u003c\/th\u003e\n        \u003cth\u003eNew Products Launched\u003c\/th\u003e\n        \u003cth\u003eAverage Selling Price of Generic Drugs (CNY)\u003c\/th\u003e\n        \u003cth\u003eGross Profit Margin (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e800 million\u003c\/td\u003e\n        \u003ctd\u003e10\u003c\/td\u003e\n        \u003ctd\u003e3.0\u003c\/td\u003e\n        \u003ctd\u003e58\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e1 billion\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003e3.5\u003c\/td\u003e\n        \u003ctd\u003e60\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003e1.2 billion\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n        \u003ctd\u003e4.0\u003c\/td\u003e\n        \u003ctd\u003e62\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBy combining high-quality products, innovative formulations, and cost-effective solutions, Sichuan Kelun Pharmaceutical Co., Ltd. effectively addresses the needs of its customer segments while differentiating itself from competitors in a rapidly evolving market. Each element of its value proposition is strategically designed to enhance customer satisfaction and loyalty, driving sustained growth and profitability within the pharmaceutical sector.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. emphasizes strong customer relationships through various strategic approaches, ensuring both client retention and satisfaction. This segment analyzes the three key components of their customer relationship strategy.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Support Services\u003c\/h3\u003e\n\n\u003cp\u003eKelun Pharmaceutical offers dedicated customer support services to address the needs of healthcare providers and patients. As of 2022, the company has reported a customer support team that handles over \u003cstrong\u003e50,000\u003c\/strong\u003e inquiries per month, showcasing their commitment to responsiveness. They maintain an average response time of \u003cstrong\u003e24 hours\u003c\/strong\u003e for inquiries, which significantly enhances customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term Partnerships with Healthcare Providers\u003c\/h3\u003e\n\n\u003cp\u003eBuilding long-term partnerships with healthcare providers is integral to Kelun's strategy. The company has established collaborations with over \u003cstrong\u003e200\u003c\/strong\u003e hospitals and healthcare institutions across China. This network not only bolsters brand loyalty but also facilitates a steady pipeline for product sales. In FY 2022, Kelun reported that approximately \u003cstrong\u003e70%\u003c\/strong\u003e of its revenues were generated from repeat orders by these partnered healthcare providers.\u003c\/p\u003e\n\n\u003ch3\u003eDigital Engagement Through Online Platforms\u003c\/h3\u003e\n\n\u003cp\u003eSichuan Kelun is also focusing on digital engagement, utilizing online platforms to manage customer relationships effectively. Their digital channels, including a comprehensive website and mobile applications, have seen a usage increase of \u003cstrong\u003e40%\u003c\/strong\u003e year-over-year as of October 2023. The company has invested around \u003cstrong\u003e¥100 million\u003c\/strong\u003e in enhancing their digital infrastructure to improve user experience and streamline service delivery.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Relationship Strategy\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003e2022 Financial Impact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDedicated Customer Support Services\u003c\/td\u003e\n    \u003ctd\u003e50,000 inquiries per month\u003cbr\u003eAverage response time: 24 hours\u003c\/td\u003e\n    \u003ctd\u003eIncreased customer satisfaction leading to repeat business\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLong-term Partnerships\u003c\/td\u003e\n    \u003ctd\u003e200 healthcare partnerships\u003cbr\u003e70% revenue from repeat orders\u003c\/td\u003e\n    \u003ctd\u003eStable revenue stream, enhancing financial predictability\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDigital Engagement\u003c\/td\u003e\n    \u003ctd\u003e40% year-over-year usage growth\u003cbr\u003eInvestment: ¥100 million\u003c\/td\u003e\n    \u003ctd\u003eImproved service delivery, driving customer acquisition\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. employs a robust direct sales force, targeting healthcare professionals and institutions. As of the latest report in 2023, the company has over \u003cstrong\u003e1,500\u003c\/strong\u003e dedicated sales representatives across China. The sales force is responsible for generating approximately \u003cstrong\u003e70%\u003c\/strong\u003e of the company's total revenue. Their strategy includes detailed product training and support for healthcare providers to enhance product knowledge and boost sales effectiveness.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution through Pharmacies and Hospitals\u003c\/h3\u003e\n\u003cp\u003eThe distribution network for Sichuan Kelun Pharmaceutical includes partnerships with over \u003cstrong\u003e5,000\u003c\/strong\u003e pharmacies and hospitals nationwide. In 2022, the company reported that around \u003cstrong\u003e60%\u003c\/strong\u003e of its pharmaceuticals were distributed directly through these healthcare facilities. This channel is significant, as the company’s total sales reached approximately \u003cstrong\u003eCNY 10 billion\u003c\/strong\u003e ($1.54 billion) in 2022, with distribution through pharmacies and hospitals accounting for a significant portion of this revenue.\u003c\/p\u003e\n\u003cp\u003eBelow is a table summarizing the distribution metrics:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eNumber of Partners\u003c\/th\u003e\n\u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n\u003cth\u003eTotal Revenue (CNY)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e35%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOnline Sales Platforms\u003c\/h3\u003e\n\u003cp\u003eSichuan Kelun Pharmaceuticals has increasingly turned to online sales to reach customers directly. By 2023, the company reported that online sales accounted for about \u003cstrong\u003e15%\u003c\/strong\u003e of total revenues, totaling approximately \u003cstrong\u003eCNY 1.5 billion\u003c\/strong\u003e ($231 million). The company collaborates with major e-commerce platforms such as JD.com and Alibaba to enhance its digital footprint.\u003c\/p\u003e\n\u003cp\u003eIn 2022, the growth in online sales was approximately \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year, reflecting a significant shift in consumer purchasing behavior, particularly post-pandemic. The digital channel includes prescription and over-the-counter medications, allowing for a broader reach to consumers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. serves a variety of customer segments, each requiring tailored approaches to better meet their specific needs. The primary segments include hospitals and clinics, pharmaceutical wholesalers, and individual consumers.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\n\u003cp\u003eHospitals and clinics represent a significant customer segment for Sichuan Kelun Pharmaceutical. In 2022, the global hospital market was valued at approximately \u003cstrong\u003e$8.45 trillion\u003c\/strong\u003e, indicating a robust environment for pharmaceutical suppliers. Furthermore, the number of hospitals in China reached around \u003cstrong\u003e38,000\u003c\/strong\u003e, with more than \u003cstrong\u003e1,000\u003c\/strong\u003e being specialized in providing comprehensive pharmaceutical care. Kelun's partnerships with hospitals focus on providing essential medications and innovative treatments.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Wholesalers\u003c\/h3\u003e\n\n\u003cp\u003ePharmaceutical wholesalers are crucial intermediaries that enable Sichuan Kelun to distribute its products efficiently. In 2021, the pharmaceutical wholesale market reached a value of approximately \u003cstrong\u003e$500 billion\u003c\/strong\u003e globally, with an expected growth rate of around \u003cstrong\u003e6%\u003c\/strong\u003e annually. Sichuan Kelun has established a network of over \u003cstrong\u003e500\u003c\/strong\u003e wholesalers, facilitating the distribution of its extensive product line to various healthcare facilities and retail pharmacies.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eSegment\u003c\/th\u003e\n        \u003cth\u003eEstimated Market Size (2022)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (CAGR)\u003c\/th\u003e\n        \u003cth\u003eNumber of Key Relationships\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e$8.45 trillion\u003c\/td\u003e\n        \u003ctd\u003e4.5%\u003c\/td\u003e\n        \u003ctd\u003e1,000+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Wholesalers\u003c\/td\u003e\n        \u003ctd\u003e$500 billion\u003c\/td\u003e\n        \u003ctd\u003e6%\u003c\/td\u003e\n        \u003ctd\u003e500+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIndividual Consumers\u003c\/td\u003e\n        \u003ctd\u003e$350 billion (China)\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\n\u003cp\u003eAlthough typically a secondary focus compared to institutional clients, individual consumers form an important segment for direct-to-consumer products. The individual consumer pharmaceutical market in China was estimated at \u003cstrong\u003e$350 billion\u003c\/strong\u003e in 2022, with an annual growth rate projected at \u003cstrong\u003e8%\u003c\/strong\u003e. This segment increasingly values over-the-counter medications and wellness products, reflecting a shift towards self-medication and preventive healthcare.\u003c\/p\u003e\n\n\u003cp\u003eIn summary, Sichuan Kelun's customer segments are diverse, encompassing hospitals, wholesalers, and individual consumers. Each segment is vital for the company’s overall strategy, emphasizing the importance of targeted engagement and tailored offerings to maximize market reach and revenue potential.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Sichuan Kelun Pharmaceutical Co., Ltd. plays a critical role in its operational efficiency and overall business strategy. Understanding the composition of costs is essential for analyzing profitability and sustainability in the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D and Innovation Expenses\u003c\/h3\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical has consistently invested significantly in research and development (R\u0026amp;D) to maintain its competitive edge. In 2022, the company's R\u0026amp;D expenditure reached approximately \u003cstrong\u003e￥2.21 billion\u003c\/strong\u003e, constituting about \u003cstrong\u003e10.7%\u003c\/strong\u003e of its total revenue. This focus on innovation is pivotal in developing new pharmaceutical products and improving existing ones.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing and Material Costs\u003c\/h3\u003e\n\n\u003cp\u003eThe manufacturing process incurs substantial fixed and variable costs, including labor, materials, and overhead. In 2022, manufacturing costs for Sichuan Kelun were around \u003cstrong\u003e￥4.5 billion\u003c\/strong\u003e, which accounted for \u003cstrong\u003e22%\u003c\/strong\u003e of total costs. Key materials include active pharmaceutical ingredients (APIs) and excipients, which contribute roughly \u003cstrong\u003e60%\u003c\/strong\u003e of the overall manufacturing expenses.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Item\u003c\/th\u003e\n        \u003cth\u003eAmount (￥ million)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e4,500\u003c\/td\u003e\n        \u003ctd\u003e22%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMaterial Costs\u003c\/td\u003e\n        \u003ctd\u003e2,700\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLabor Costs\u003c\/td\u003e\n        \u003ctd\u003e1,800\u003c\/td\u003e\n        \u003ctd\u003e9%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOverhead Costs\u003c\/td\u003e\n        \u003ctd\u003e1,000\u003c\/td\u003e\n        \u003ctd\u003e5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Manufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e4,500\u003c\/td\u003e\n        \u003ctd\u003e22%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eMarketing and Distribution Costs\u003c\/h3\u003e\n\n\u003cp\u003eMarketing and distribution are crucial for reaching customers and driving sales. In 2022, Sichuan Kelun Pharmaceutical allocated approximately \u003cstrong\u003e￥1.05 billion\u003c\/strong\u003e to marketing and distribution, accounting for about \u003cstrong\u003e5.1%\u003c\/strong\u003e of the total expenditure. This includes promotional activities, salesforce salaries, and logistics costs.\u003c\/p\u003e\n\n\u003cp\u003eThe breakdown of marketing and distribution costs includes:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eDirect Marketing: \u003cstrong\u003e￥500 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eLogistics and Distribution: \u003cstrong\u003e￥350 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eSalesforce Expenses: \u003cstrong\u003e￥200 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBy maintaining a balanced cost structure that emphasizes R\u0026amp;D and efficient manufacturing while ensuring effective marketing strategies, Sichuan Kelun Pharmaceutical Co., Ltd. continues to position itself strategically within the global pharmaceutical market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSichuan Kelun Pharmaceutical Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eSichuan Kelun Pharmaceutical Co., Ltd. generates revenue through multiple streams tailored to its diverse customer segments in the pharmaceutical industry. Below are the primary revenue streams for the company.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales to Healthcare Institutions\u003c\/h3\u003e\n\n\u003cp\u003eKelun Pharmaceutical derives a significant portion of its revenue through product sales to healthcare institutions. In 2022, the company reported sales to this segment totaling approximately \u003cstrong\u003eRMB 5.23 billion\u003c\/strong\u003e, representing about \u003cstrong\u003e65%\u003c\/strong\u003e of its overall revenue. Key products include generics and proprietary medications primarily targeting hospitals and clinics across China.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing and Royalties\u003c\/h3\u003e\n\n\u003cp\u003eThe company also engages in licensing agreements, allowing it to generate revenue from intellectual property. This stream contributed around \u003cstrong\u003eRMB 1.1 billion\u003c\/strong\u003e in 2022, accounting for approximately \u003cstrong\u003e13%\u003c\/strong\u003e of total revenue. Licensing deals typically pertain to patents for innovative drug formulations and manufacturing processes.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Retail Sales to Consumers\u003c\/h3\u003e\n\n\u003cp\u003eDirect retail sales to consumers constitute another crucial revenue stream for Kelun Pharmaceutical. In 2022, revenues from this segment amounted to approximately \u003cstrong\u003eRMB 1.67 billion\u003c\/strong\u003e, which is about \u003cstrong\u003e20%\u003c\/strong\u003e of the company's total revenue. This includes over-the-counter (OTC) medications and health products sold through pharmacies and online platforms.\u003c\/p\u003e\n\n\u003ctable\u003e\n   \u003ctr\u003e\n      \u003cth\u003eRevenue Stream\u003c\/th\u003e\n      \u003cth\u003eAmount (RMB)\u003c\/th\u003e\n      \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eProduct Sales to Healthcare Institutions\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e5.23 billion\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e65%\u003c\/strong\u003e\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eLicensing and Royalties\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e1.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eDirect Retail Sales to Consumers\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e1.67 billion\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n   \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Sichuan Kelun Pharmaceutical Co., Ltd. effectively diversifies its revenue streams through healthcare institution sales, licensing agreements, and direct consumer retail, ensuring robust financial health and market presence.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45660660007061,"sku":"002422sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002422sz-business-model-canvas.png?v=1739108846","url":"https:\/\/dcf-model.com\/fr\/products\/002422sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}